MAPT and Alzheimer disease: Currently, clinical biomarkers of AD primarily include changes in levels of tau proteins (total tau and phosphorylated tau) and β-amyloid 1–42 peptide in cerebrospinal fluid (Botello-Marabotto et al., 2023).